BBIO vs ROP · rev $221.9M vs P/E 41, rev $1.88B
BridgeBio Pharma Inc (BBIO) versus Roper Technologies, Inc. (ROP) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
Roper Technologies, Inc. (ROP) is a software - application company listed on US.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
Latest reported ROP revenue for 2024-12-31 was $1.88B. Net income was $462.3M. Revenue was up 6.4% from 2024-09-30 to 2024-12-31. ROP currently screens at market cap $61.61B and trailing P/E 41.3.
BBIO currently screens at market cap $13.24B. ROP currently screens at market cap $61.61B and trailing P/E 41.3.
Not investment advice. Open the BBIO and ROP stock pages for the full models.
Not investment advice.